TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Follow-up Durability (Efficacy) Study of EN3835 for the Treatment of AC of the Shoulder (Frozen Shoulder)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Have been enrolled and completed the EN3835-210 or pivotal Phase 3 parent studies (for Study EN3835-223 eligibility, completed participants are those who were assessed for safety and obtained ASES scores at Day 95/EOS Visit; does not include early terminated participants).~2. Be willing not to use pain medications for the duration of the study period and for 2 weeks prior to the Day 180 visit. Pain medications include but are not limited to: barbiturates, benzodiazepines, methadone, buprenorphine, opioids (e.g., codeine, heroin, hydrocodone, hydromorphone, morphine, oxycodone), and cannabis.~   Note: NSAIDs (ibuprofen, etc.) are allowed.~3. Be willing to undergo MRI of the affected shoulder as required by the protocol.~4. Be able to read, understand, and independently complete patient reported outcome instruments in English.~5. Be willing and able to cooperate with the requirements of the study.~6. Be adequately informed and understand the nature and risks of the study and be able to provide consent.~Exclusion Criteria:~1. Is from a vulnerable population, as defined by the US Code of Federal Regulations (CFR) Title 45, Part 46, Section 46.111(b) and other local and national regulations, including but not limited to, employees (temporary, part-time, full time, etc.) or a family member of the research staff conducting the study, or of the sponsor, or of the contract research organization, or of the IRB/IEC.~2. Plans to receive (or received prior to Day 180) any invasive or minimally invasive (ie, steroid injections, shoulder manipulation, surgery, etc.) procedures to the affected shoulder during study participation.~   Note: PT is allowed. Any PT received should be captured in the respective electronic case report form (eCRF).~3. Has any contraindications for MRI (implant containing metal, internal metallic object, permanent cosmetics/make-up/tattoos-with exemption of the area to be treated/reviewed, claustrophobia, syncope, low blood pressure, epilepsy, asthma, anemia, or sickle cell disease) as determined by the technologist, the radiologist, and/or investigator performing imaging.~4. Has any other conditions that, in the investigator's opinion, might indicate the participant to be unsuitable for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EN3835 (Type: None): Previously treated with EN3835 in EN3835-210 or the pivotal phase 3 studies
- Placebo (Type: None): Previously treated Placebo in EN3835-210 or the pivotal phase 3 studies

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Predicting Arrhythmogenic Risk in Congenital Heart Patients: the PRECISION Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged \< 18 years of age on admission to the cardiac intensive care unit following cardiac surgery with a predicted probability of supraventricular tachycardia \>10%~Exclusion Criteria:~* Patients following orthotopic heart transplant, ventricular assist device implantation, primary extracorporeal membrane oxygenation cannulation, pacemaker or implantable cardioverter-defibrillator implantation or sympathectomy~* Patients on antiarrhythmic medication at the time of surgery~* Patients with atrioventricular conduction disease (1st degree atrioventricular block with PR interval greater than 200 ms, 2nd degree atrioventricular block or complete heart block)~* Patients with severe ventricular dysfunction in whom therapy with beta-blocker or sotalol is deemed contra-indicated by the primary team~* Patients with absent or non-functioning atrial pacing wires

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Observation (Type: NO_INTERVENTION): Patients will be observed for arrhythmias and treated if they occur.
- Testing (Type: EXPERIMENTAL): Patients will undergo provocative electrophysiology testing, and antiarrhythmic medication considered if arrhythmias can be induced.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Qualitative Pain Measurement at Patients With Degenerative Low Back Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients who are going to be treated surgically for spondylitis~* ability to understand Danish in order to filling in a questionnaire~* a written signed statement of consent~Exclusion Criteria:~* removal of implants~* diabetic neuropathy or another neuropathic disease~* neurological diseases~* unability to read or understand Danish

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Pre-operative pain measurement (Type: None): Patients with low back pain

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer Who Are Undergoing Radiation Therapy and/or Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion~* Written informed consent must be obtained from all participants prior to beginning therapy; participants should have the ability to understand and be willing to sign a written informed consent document~* Primary diagnosis of head and neck carcinoma (oral, hypopharyngeal, laryngeal)~* Stage I-IV, undergoing treatment with radiation therapy +/- chemotherapy~Exclusion~* Medical history of esophageal dysfunction~* Pregnant women are not excluded from participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients undergo transnasal esophagoscopy at baseline and 3 months following completion of radiation therapy and/or chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Positron Emission Tomography (PET)-Computed Tomography (CT) in Inflammatory Bowel Disease (IBD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient with either Crohn's disease or ulcerative colitis whose disease is flaring~Exclusion Criteria:~* Indeterminate diagnosis, pregnant, breastfeeding, or other contraindication to PET-CT

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Liquid Bandage (2-Octyl-Cyanoacrylate) in Upper Lid Blepharoplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients older than 25 years with diagnosis of dermatochalasis who presented surgical indication of primary blepharoplasty.~Exclusion Criteria:~* Prior eyelid surgery~* Concomitant ocular or systemic disease or current use of medications that could interfere in coagulation or wound healing (eg, diabetes mellitus, oral acetyl salicylic acid or corticosteroids)~* Pregnant female~* Known allergy to cyanoacrylate~* Inability to return for follow-up consultations

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Experimental operatory wound closure with liquid bandage (Johnson \& Johnson, Skillman, NJ, USA).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Confirmed squamous cell carcinoma (SCC) of the head and neck (oropharynx, oral cavity, hypopharynx, or larynx) or skin~* For patients with oropharyngeal cancer, p16 status is known or can be determined~* Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)~* Acceptable laboratory results as indicated by protocol~* Acceptable cardiac function as indicated by protocol~Exclusion Criteria:~* Received prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy for recurrent or metastatic Squamous Cell Carcinoma (e.g., oral EGFR TKIs such as erlotinib, gefitinib, or afatinib)~* Family history of long corrected QT interval (QTc) syndrome~* Receiving medication that prolongs QT interval ,with a risk of causing Torsades de Pointes (TdP), unless ECG meets inclusion criteria while on a stable dose of the medication~* Family history of long QTc syndrome~* Symptomatic central nervous system (CNS) lesions, or CNS lesions that require therapy~* Radiation therapy within 2 weeks prior to the first dose of study medication~* Major surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose of study medication~* Concurrent active malignancy requiring systemic treatment~* Any other serious uncontrolled medical disorders or psychological conditions that may interfere with study conduct including but not limited to: clinically significant active infection~* Pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TH-4000 (Tarloxotinib) (Type: EXPERIMENTAL): TH-4000 150 mg/m2 will be administered by IV infusion over 60 minutes on Days 1, 8, 15 and 22 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects or female subjects of non-childbearing potential~* ≥18 and \<55 years of age at the time of consent~* BMI \>18.5 and \<30 kg/m2 and a weight of ≥50 kg for males or ≥45 kg for females~* Sexually active males must use a double barrier method of contraception during the study and for at least 90 days after the last dose of study drug~* Male subjects must be willing not to donate sperm until 90 days following the last study drug administration~Exclusion Criteria:~* Personal or family History of significant medical illness~* Clinically significant abnormalities on screening tests/exams~* History of or significant risk of committing suicide~* Donation of plasma within 7 days prior to dosing~* Donation or significant loss of blood within 30 days prior to the first dosing~* Major surgery within 3 months or minor surgery within 1 month prior to admission~* Use of prohibited prescription, over-the-counter medications or natural health products~* Alcohol-based products 24 hours prior to admission~* Female subjects who are currently pregnant or lactating~* Positive pregnancy test~* Use of tobacco or nicotine products within 3 months prior to Screening~* Significant alcohol consumption~* History of drug abuse within the previous 2 years, or a positive drug screen~* History of allergy to study medications~* Undergoing abrupt discontinuation of alcohol or sedatives~* Not suitable for study in the opinion of the Principal Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: OTHER): ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 1 Probe Cocktail given on 2 separate days:~* midazolam: 1 µg infused IV~* caffeine: 200 mg oral tablet~* omeprazole: two 20 mg oral tablets~* dextromethorphan: 1.6mL (containing \~10 mg) oral solution
- Cohort 2 (Type: OTHER): ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 2 Probe Cocktail given on 3 separate days:~* midazolam: 10 µg/mL given as 1mL oral solution.~* dabigatran: 375 µg/mL and pitavastatin: 10 µg/mL given as 1mL oral solution~* rosuvastatin: 25 µg/mL and atorvastatin: 50 µg/mL given as 2mL oral solution
- Cohort 3 (Type: OTHER): ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 3 Probe Cocktail given on 2 separate days:~- bupropion: 100mg oral tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Physiologic Elasticity Changes During Pregnancy and After Labor.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pregnant patients in their 2nd trimester.~Exclusion Criteria:~* Pregnant patients presenting after their 2nd trimester.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Pregnant patients (Type: None): Pregnant patients in their 2nd trimester.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult participants with a diagnosis of non-Hodgkin's lymphoma, chronic lymphocytic leukemia or multiple myeloma~* Anemia at Screening Visit~Exclusion Criteria:~* Transfusion of red blood cells within 2 months of study drug~* Treatment-resistant hypertension~* Acute or chronic bleeding (requiring therapy) within 3 months of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Epoetin Beta - 30000 IU (Type: EXPERIMENTAL): Dosage at Initiation: Subcutaneous injection of 30000 IU epoetin beta administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 grams per deciliter (g/dL) versus baseline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Patients are included if they meet all of the following inclusion criteria:~* Cataract on one or both eyes~* Study eye with non-exudative AMD AREDS I - III~* Men or women aged between 60 - 99 years~* Patient planned for cataract surgery and in need of an intraocular lens~Exclusion Criteria:~Patients are excluded if they meet one or more of the following exclusion criteria:~* Study eye with exudative AMD~* Study eye with concomitant retinal or choroidal disorder other than AMD~* Study eye with significant keratopathies~* Fundus not visible~* Intake of medication known to affect melatonin secretion (within the last 12 hours): ß-blockers, calcium channel blockers, a-blockers, non-steroidal anti-inflammatory drugs, benzodiazepines, antidepressants, hypnotic drugs, antipsychotics, barbiturates, antiepileptic drugs, and melatonin~* Alcohol or caffeine consumption 6 hours before vein puncture~* Patients who are unwilling to adhere to visit examination schedules

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): White Alcon IOL
- 2 (Type: ACTIVE_COMPARATOR): Yellow Alcon IOL
- 3 (Type: ACTIVE_COMPARATOR): White Hoya IOL
- 4 (Type: ACTIVE_COMPARATOR): Yellow Hoya IOL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: LYT-100 in Patients With BCRL

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Female or male between 18 and 80 years old (inclusive) at the time of informed consent.~2. At least 6 months since any type of breast cancer surgery (excluding fine needle aspiration biopsy \[FNA\]), at the time of study screening. No intention to have breast reconstructive surgery, nipple reconstruction and/or tattooing during the course of the study.~3. At least 3 months since completion of all types of treatment for breast cancer, including but not limited to neoadjuvant, radiotherapy, chemotherapy and immunotherapy, at the time of study screening.~4. At least 3 months treatment of stable adjuvant treatment with hormonal or anti-HER2 therapy at the time of screening, with no planned changes to this therapy throughout the duration of the study.~5. Diagnosis of primary breast cancer, and without evidence of recurrence of breast cancer and/or metastasis for at least 6 months since breast cancer surgery, as determined at screening and baseline.~6. Documented evidence of Stage 1 or 2 lymphedema.~7. Receiving standard of care compression or agreeable to using care compression, or no compression at all ≥ 4 weeks prior to screening and throughout the study.~Main Exclusion Criteria:~1. Bilateral lymphoedema or history of bilateral axillary lymph node removal (i.e., sentinel lymph node or axillary lymph node dissection), or primary lymphoedema or lymphatic or vascular malformation, determined at screening.~2. Chronic administration (defined as more than 14 consecutive days) of immunosuppressants or other immune-modifying drugs within 3 months prior to study drug administration; corticosteroids are permitted at the discretion of the PI.~3. Recent history (in the 8 weeks prior to screening) of cellulitis, lymphangitis, dermatitis, necrotizing fasciitis, or current open wounds or sores in the affected extremity.~4. Stage III lymphoedema, or history of clinically diagnosed secondary lymphoedema greater than 4 years, determined at screening.~5. Initiated use of compression or manual lymphatic drainage or other lymphoedema therapies at the start of the study within 4 weeks of the screening visit. Rescreening is allowed following a course of stable compression regimen of \> 4 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- LYT-100 in patients with BCRL (Type: EXPERIMENTAL): LYT-100 BID for 6 months
- Placebo in patients with BCRL (Type: PLACEBO_COMPARATOR): Placebo BID for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy